Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PTLA's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: No Debt )
PTLA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.82
PTLA's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 0.82 )
PTLA' s 10-Year Equity to Asset Range
Min: -1.31   Max: 0.91
Current: 0.82

-1.31
0.91
Interest Coverage No Debt
PTLA's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: No Debt )
PTLA' s 10-Year Interest Coverage Range
Min: 946.14   Max: 9999.99
Current: No Debt

946.14
9999.99
Z-Score: 10.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1114.61
PTLA's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: -1114.61 )
PTLA' s 10-Year Operating margin (%) Range
Min: -799.34   Max: 25.46
Current: -1114.61

-799.34
25.46
Net-margin (%) -1099.77
PTLA's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: -1099.77 )
PTLA' s 10-Year Net-margin (%) Range
Min: -791.49   Max: 25.61
Current: -1099.77

-791.49
25.61
ROE (%) -43.32
PTLA's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: -43.32 )
PTLA' s 10-Year ROE (%) Range
Min: -159.12   Max: -159.12
Current: -43.32

ROA (%) -37.46
PTLA's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: -37.46 )
PTLA' s 10-Year ROA (%) Range
Min: -35.34   Max: 20.67
Current: -37.46

-35.34
20.67
ROC (Joel Greenblatt) (%) -4087.07
PTLA's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: -4087.07 )
PTLA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3082.88   Max: 1022.07
Current: -4087.07

-3082.88
1022.07
» PTLA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.50
PTLA's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 4.50 )
PTLA' s 10-Year P/B Range
Min: 3.07   Max: 5.24
Current: 4.5

3.07
5.24
P/S 105.90
PTLA's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 105.90 )
PTLA' s 10-Year P/S Range
Min: 5.28   Max: 122.44
Current: 105.9

5.28
122.44
Current Ratio 6.60
PTLA's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 6.60 )
PTLA' s 10-Year Current Ratio Range
Min: 5.12   Max: 10.67
Current: 6.6

5.12
10.67
Quick Ratio 6.60
PTLA's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 6.60 )
PTLA' s 10-Year Quick Ratio Range
Min: 5.12   Max: 10.67
Current: 6.6

5.12
10.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
PTLA's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 6.50 )
PTLA' s 10-Year Price/Net Cash Range
Min: 4.4   Max: 6.87
Current: 6.5

4.4
6.87
Price/Net Current Asset Value 6.50
PTLA's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 6.50 )
PTLA' s 10-Year Price/Net Current Asset Value Range
Min: 4.4   Max: 6.87
Current: 6.5

4.4
6.87
Price/Tangible Book 4.70
PTLA's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 4.70 )
PTLA' s 10-Year Price/Tangible Book Range
Min: 3.56   Max: 5
Current: 4.7

3.56
5
Price/Median PS Value 10.10
PTLA's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PTLA: 10.10 )
PTLA' s 10-Year Price/Median PS Value Range
Min: 0.59   Max: 10.65
Current: 10.1

0.59
10.65

Business Description

Industry: »
Compare: » details
Traded in other countries:0PP.Germany
Portola Pharmaceuticals Inc was incorporated in Delaware in September 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Its two programs address significant unmet medical needs in the areas of thrombosis or blood clots. Its compound Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism, or VTE, in acute medically ill patients. The Company's current product candidates in development includes: Betrixaban, PRT4445, PRT2070, and PRT2607. Betrixaban is a novel oral once-daily inhibitor of Factor Xa in development for extended duration VTE prophylaxis in acute medically ill patients for up to 35 days. PRT4445 is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. PRT2070 is an orally available, potent inhibitor of Syk and JAK. PRT2607 is an orally available, potent and selective inhibitor of Syk. The Company faces competition from large and small pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies and research institutions and others.
» More Articles for PTLA

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 

More From Other Websites
Portola Pharmaceuticals Announces Commercial Supply Agreement for Andexanet Alfa With Lonza Oct 16 2014
Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza Oct 16 2014
Portola Pharmaceuticals Announces Commercial Supply Agreement for Andexanet Alfa With Lonza Oct 16 2014
3 Big-Volume Biotech Stocks to Trade for Breakouts Oct 06 2014
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 03 2014
Portola Announces Pricing of Public Offering of Common Stock Oct 02 2014
Portola Pharmaceuticals Announces Proposed Offering of Common Stock Oct 01 2014
Portola Pharma drug reverses effect of anti-clotting drugs in study Oct 01 2014
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 01 2014
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis... Oct 01 2014
Portola Pharmaceuticals to Present at the 2014 Morgan Stanley Global Healthcare Conference Sep 02 2014
Insider Trading Alert - PTLA, TAL And EAT Traded By Insiders Aug 26 2014
Zacks Rank #1 Additions for Thursday Aug 21 2014
PORTOLA PHARMACEUTICALS INC Financials Aug 15 2014
Cardiome Pharma Corp. (CRME) Jumps: Stock Rises 6.9% Aug 12 2014
Aratana Therapeutics (PETX) Falls: Stock Goes Down 5.9% Aug 12 2014
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2014
PORTOLA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
Portola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 06 2014
Portola Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update Aug 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK